Home › Myasthenia Gravis
Myasthenia Gravis clinical trials recruiting in the U.S.
45 studies for Myasthenia Gravis are recruiting participants at sites across the United States.
Myasthenia gravis (MG) is an autoimmune disease that weakens the muscles under your control. Find out about MG causes, symptoms, and treatment.
Cities with the most studies
- Tampa, FL12 studies
- Houston, TX11 studies
- Durham, NC10 studies
- Boca Raton, FL10 studies
- Columbus, OH8 studies
- Milwaukee, WI7 studies
- New York City, NY7 studies
- Miami, FL7 studies
- St. Louis, MO7 studies
- Columbia, MO6 studies
- Charleston, SC6 studies
- San Francisco, CA6 studies
- Washington, DC6 studies
- Dallas, TX6 studies
- Detroit, MI6 studies
- Kansas City, KS6 studies
- Boston, MA6 studies
- Portland, OR6 studies
- Orange, CA6 studies
- Jacksonville, FL6 studies
- Chattanooga, TN6 studies
- Austin, TX6 studies
- Philadelphia, PA6 studies
- Lexington, KY5 studies
- Scottsdale, AZ5 studies
- Port Charlotte, FL5 studies
- Cincinnati, OH5 studies
- Aurora, CO5 studies
- New Haven, CT4 studies
- Augusta, GA4 studies
- Los Angeles, CA4 studies
- Chicago, IL4 studies
- Amherst, NY4 studies
- Mountain View, CA4 studies
- Clearwater, FL3 studies
- Brockton, MA3 studies
- Raleigh, NC3 studies
- Phoenix, AZ3 studies
- Carlsbad, CA3 studies
- Lansing, MI3 studies
By state
- Arizona7 studies
- California20 studies
- Colorado8 studies
- Connecticut6 studies
- District of Columbia6 studies
- Florida22 studies
- Georgia4 studies
- Illinois12 studies
- Indiana3 studies
- Kansas7 studies
- Kentucky6 studies
- Massachusetts11 studies
- Michigan12 studies
- Minnesota3 studies
- Missouri7 studies
- Nevada3 studies
- New Jersey3 studies
- New York13 studies
- North Carolina14 studies
- Ohio13 studies
- Oregon8 studies
- Pennsylvania6 studies
- South Carolina7 studies
- Tennessee10 studies
- Texas18 studies
- Virginia3 studies
- Wisconsin7 studies
Recently updated studies
A Study to Evaluate the Efficacy and Safety of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT07463521A Phase 3 Study to Evaluate Claseprubart in Adults With Generalized Myasthenia Gravis (EMERGE)
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Sep 25, 2026 · NCT07647510Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis
RecruitingPhase 3
Ages 18 to 74 · All sexes · Updated Sep 25, 2026 · NCT07217587A Study to Evaluate The Long-Term Safety And Efficacy of Rozanolixizumab in Adult Participants With Ocular Myasthenia Gravis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07465289ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07294170ADAPT Forward 2 - ISA2 - a Study to Evaluate the Safety, Tolerability and Efficacy of Empasiprubart IV Monotherapy in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07673627ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 24, 2026 · NCT07284420A Study to Evaluate the Efficacy and Safety of Maintenance Ublituximab Following Induction With Efgartigimod Administration in Participants With Myasthenia Gravis (MG)
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07673744Efficacy and Safety of a New Formulation of Oral Cladribine Compared With Placebo in Participants With Generalized Myasthenia Gravis (MyClad)
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 16, 2026 · NCT06463587A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 11, 2026 · NCT07501702A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 9, 2026 · NCT06680037A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
RecruitingPhase 2
Ages 2 to 17 · All sexes · Updated Sep 1, 2026 · NCT06987539Zilucoplan for Severe gMG Exacerbations
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Aug 28, 2026 · NCT07215949Feasibility of Remote Monitoring of Patients With Myasthenia Gravis
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 26, 2026 · NCT07787247Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 21, 2026 · NCT06414954AXIS MG Patient Registry
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT07761026A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
RecruitingPhase 1
Ages 18 to 75 · All sexes · Updated Aug 14, 2026 · NCT07304154RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecruitingPhase 1/2
Ages 18 to 70 · All sexes · Updated Aug 13, 2026 · NCT06359041Pregnancy Registry, Infants, Serum/Milk Analysis (PRISMA)
RecruitingObservational studyHealthy volunteers welcome
Ages 18 to 64 · Women · Updated Aug 11, 2026 · NCT06940323MuSK Myasthenia 1000 Study
RecruitingObservational study
Ages 7 to 99 · All sexes · Updated Aug 5, 2026 · NCT06259071Study of Aritinercept in Patients With Generalized Myasthenia Gravis
RecruitingPhase 1/2
Ages 18 to 85 · All sexes · Updated Aug 3, 2026 · NCT07596901A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis
RecruitingPhase 2/3
Ages 2 to 17 · All sexes · Updated Jul 31, 2026 · NCT05265273Study to Assess the Efficacy and Safety of IMVT-1402 in Participants With Mild to Severe Generalized Myasthenia Gravis
RecruitingPhase 3
Ages 18 to 80 · All sexes · Updated Jul 30, 2026 · NCT07039916KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis
RecruitingPhase 2/3
Ages 18 to 75 · All sexes · Updated Jul 29, 2026 · NCT06193889A Study of Nipocalimab Administered to Adults With Generalized Myasthenia Gravis
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Jul 27, 2026 · NCT04951622From ClinicalTrials.gov, data retrieved Sep 29, 2026. Each study sets its own eligibility; the study team decides who can join.